Skip to main content
Cellectar Biosciences, Inc. logo

Cellectar Biosciences, Inc. — Investor Relations & Filings

Ticker · CLRB ISIN · US15117F8077 LEI · 5493000NFZCRG7BYQV93 US Manufacturing
Open in API
Filings indexed 1,033 across all filing types
Latest filing 2011-04-11 M&A Activity
Country US United States of America
Listing US CLRB

About Cellectar Biosciences, Inc.

https://www.cellectar.com/

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted cancer treatments. The company's core technology is a proprietary Phospholipid Drug Conjugate (PDC) platform that selectively delivers therapeutic payloads, such as radioisotopes and cytotoxins, to cancer cells by targeting lipid rafts in their plasma membranes. This approach is designed to maximize antitumor activity while minimizing off-target effects on healthy tissue. Cellectar's lead product candidate is iopofosine I 131, a first-in-class PDC that delivers the radioisotope iodine-131. It is being developed for the treatment of hematologic malignancies and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for Waldenstrom's Macroglobulinemia.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
M&A Activity Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes details about a merger agreement, completion of acquisition, issuance of shares, changes in control, and changes in the board of directors. It specifically describes the merger transaction, securities purchase agreement, and changes in the board of directors including resignations and new appointments. These elements correspond to announcements about merger activity and management changes. The presence of detailed merger agreement information and changes in control and board composition indicates this is primarily a merger-related filing with management changes. According to the filing definitions, announcements related to merger proposals or takeover bids fall under "M&A Activity (TAR)" and announcements of changes in the company's board or senior management fall under "Board/Management Information (MANG)". Since the document covers both but is primarily focused on the merger and acquisition event, the best classification is "M&A Activity (TAR)". The document is not a full annual or quarterly report, nor an earnings release, nor a proxy or voting announcement. It is a regulatory filing of a current report type but specifically about merger and acquisition activity.
2011-04-11 English
Regulatory Filings 2011
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25, which is a Notification of Late Filing submitted to the SEC. It specifically states that the registrant, Novelos Therapeutics, Inc., could not file its Form 10-K for the year ended December 31, 2010, within the prescribed time period and requests an extension. The document does not contain the actual 10-K report or financial data but is an announcement related to the delay in filing the annual report. According to the MENU VS MEAL RULE, such a notification is classified as a Regulatory Filing (RNS) because it is a compliance document notifying the SEC of a late filing rather than the report itself.
2011-04-01 English
Board/Management Information 2011
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The text specifically mentions Item 5.02, which relates to the departure of directors or principal officers and appointment of principal officers. The content describes the termination of a Vice President and related payment details. The document length is short (2316 characters), and it contains direct information about management changes rather than a report or announcement of a report. Therefore, it fits the category of Board/Management Information (MANG).
2011-03-16 English
Major Shareholding Notification 2011
Major Shareholding Notification
2011-02-14 English
NOVELOS13GAM1
Major Shareholding Notification
2011-02-14 English
Regulatory Filings 2011
Regulatory Filings
2011-02-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.